Assessing the Effectiveness of Screening, Brief Intervention, and Referral to Treatment (SBIRT) With Personalized Feedback Intervention to Reduce Polysubstance Impaired Driving in Young Adults Aged 18-30 (ADAPT)

January 20, 2026 updated by: Brittney Hultgren, University of Washington
The current study is assessing the effects of receiving Screening, Brief Intervention and Referral to Treatment alone versus also receiving a brief online personalized intervention on impaired driving behaviors among Washington State young adults aged 18-30.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The current project is inviting young adult aged 18-30 in Washington State who screen at moderate or moderate to high risk or who report impaired driving during Screening, Brief Intervention and Referral to Treatment. Consented young adults would be randomized to receive a brief online personalized intervention or waitlist control and be assessed at enrollment and 3 months later. A selection of participants will be assessed at 6 months.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
600

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Brittney Hultgren, PhD
  • Phone Number: 206-221-4657
  • Email: hultgren@uw.edu

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged 18-30 at enrollment
  • Received Screening, Brief Intervention, and Referral to Treatment (SBIRT) in the past 3 month
  • Through SBIRT screened at moderate or moderate-to-high risk based on substance use OR reported any impaired driving the past 6 months
  • Lives in Washington State
  • Received a study information card from an SBIRT provider
  • Consents to having Zip Code use for analyses
  • Consents to randomization to receive brief online personalized intervention or waitlist control

Exclusion Criteria:

  • Not meeting eligibility criteria
  • Inability to confirm participant's identity, residency, or date received SBIRT.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Waitlist control
Individuals will have received SBIRT but will be on a waitlist to receive the brief personalized intervention for 3 months after baseline assessment.
Behavioral: Personalize Feedback Intervention
The brief online personalized feedback intervention (PFI) is adapted from the personalized feedback provided in BASICS, iCHAMP, studies using similar standalone PFI approaches. Specifically, feedback adapted from these brief motivational interventions and prior projects include: Patterns of use: alcohol, cannabis, other drug, and polysubstance use frequency, alcohol and cannabis quantity and peak; Substance use norms; Expectancies of use of alcohol ; Estimates on money the participant spends on alcohol and cannabis compared; Protective behavioral strategies; Alcohol- and/or cannabis-impaired driving norms; Wait time to drive and related psychoeducation; Additional psychoeducation is provided (e.g., standard drink; information on tetrahydrocannabinol (THC) percentages) throughout the feedback to improve understanding and motivation for change.
Experimental: Active Intervention
Participants will have received SBIRT and receive the brief online personalized intervention immediately after baseline assessment.
Behavioral: Personalize Feedback Intervention
The brief online personalized feedback intervention (PFI) is adapted from the personalized feedback provided in BASICS, iCHAMP, studies using similar standalone PFI approaches. Specifically, feedback adapted from these brief motivational interventions and prior projects include: Patterns of use: alcohol, cannabis, other drug, and polysubstance use frequency, alcohol and cannabis quantity and peak; Substance use norms; Expectancies of use of alcohol ; Estimates on money the participant spends on alcohol and cannabis compared; Protective behavioral strategies; Alcohol- and/or cannabis-impaired driving norms; Wait time to drive and related psychoeducation; Additional psychoeducation is provided (e.g., standard drink; information on tetrahydrocannabinol (THC) percentages) throughout the feedback to improve understanding and motivation for change.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Number of times in the past 3 months participants drove impaired by both alcohol and cannabis at 3 month follow-up
Time Frame: From baseline to 3 months later at 3 month follow up assessment.
From baseline to 3 months later at 3 month follow up assessment.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number of times in the past 3 months participants drove impaired by both alcohol and cannabis at 6 month follow-up
Time Frame: From 3 month after completing baseline to 3 months later at the 6 month follow-up assessment
From 3 month after completing baseline to 3 months later at the 6 month follow-up assessment
Number of times in the past 3 months participants drove impaired by alcohol only at 3 month follow-up
Time Frame: From baseline to 3 months later at 3 month follow-up assessment
From baseline to 3 months later at 3 month follow-up assessment
Number of times in the past 3 months participants drove impaired by cannabis only at 3 month follow-up
Time Frame: From baseline to 3 months later at 3 month follow-up assessment
From baseline to 3 months later at 3 month follow-up assessment
Number of times in the past 3 months participants drove impaired by alcohol only at 6 month follow-up
Time Frame: From 3 months after baseline to 3 months later at 6 month follow-up assessment
From 3 months after baseline to 3 months later at 6 month follow-up assessment
Number of times in the past 3 months participants drove impaired by cannabis only at 6 month follow-up
Time Frame: From 3 months after baseline to 3 months later at 6 month follow-up assessment
From 3 months after baseline to 3 months later at 6 month follow-up assessment
Reported wait time to drive after using both alcohol and cannabis measured in minutes at 3 month follow up
Time Frame: From baseline to 3 months later at 3 month follow up assessment.
Question asks: How long do you typically wait to drive after using alcohol and Cannabis used at the same time so that the effects overlap. Participants answer in hours and minutes which is transformed into total number of minutes.
From baseline to 3 months later at 3 month follow up assessment.
Reported wait time to drive after using alcohol measured in minutes at 3 month follow up
Time Frame: From baseline to 3 months later at 3 month follow up assessment.
Question asks: How long do you typically wait to drive after using alcohol. Participants answer in hours and minutes which is transformed into total number of minutes.
From baseline to 3 months later at 3 month follow up assessment.
Reported wait time to drive after using cannabis measured in minutes at 3 month follow up
Time Frame: From baseline to 3 months later at 3 month follow up assessment.
Question asks: How long do you typically wait to drive after using cannabis. Participants answer in hours and minutes which is transformed into total number of minutes.
From baseline to 3 months later at 3 month follow up assessment.
Reported wait time to drive after using both alcohol and cannabis measured in minutes at 6 month follow up
Time Frame: From 3 months after baseline to 3 months later at 6 month follow-up assessment
Question asks: How long do you typically wait to drive after using alcohol and Cannabis used at the same time so that the effects overlap. Participants answer in hours and minutes which is transformed into total number of minutes.
From 3 months after baseline to 3 months later at 6 month follow-up assessment
Reported wait time to drive after using alcohol measured in minutes at 6 month follow up
Time Frame: From 3 months after baseline to 3 months later at 6 month follow-up assessment
Question asks: How long do you typically wait to drive after using alcohol . Participants answer in hours and minutes which is transformed into total number of minutes.
From 3 months after baseline to 3 months later at 6 month follow-up assessment
Reported wait time to drive after using cannabis measured in minutes at 6 month follow up
Time Frame: From 3 months after baseline to 3 months later at 6 month follow-up assessment
Question asks: How long do you typically wait to drive after using cannabis. Participants answer in hours and minutes which is transformed into total number of minutes.
From 3 months after baseline to 3 months later at 6 month follow-up assessment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Washington

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 31, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 20, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 27, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY00023076
  • U01CE003725 (U.S. NIH Grant/Contract)
  • Project 7744 (Other Grant/Funding Number: Insurance Institute of Highway Safety)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings